Phaco after trab may increase bleb failure rates at 1 year, but not 2 years

Article

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recently published study.

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recent study published in Clinical & Experimental Ophthalmology.

For this retrospective case control study, Dan Q Nguyen, FRCOphth, and fellow researchers at the University of Melbourne and the Royal Victorian Eye & Ear Hospital, Melbourne, Australia, included 48 patients who had undergone trabeculectomy and ≄2 years of follow-up. Patients were classified into two groups: those who had phacoemusification subsequent to trabeculectomy (trab_phaco; n = 18), and those who were pseudophakic for >6 months preceding trabeculectomy (Phaco_trab; n = 30). These groups were matched for length of follow-up of 2 years from time of trabeculectomy.

Researchers found no significant differences between the groups in achieving the primary outcome measures of target IOP of criteria A ≀12 mmHg, criteria B ≀15 mmHg, or criteria C ≀18 mmHg with or without additional topical treatment at 12 months (P = 1.0) and at 24 months (P = 0.330). In the first 12 months, significantly more trabeculectomies failed in the Trab_phaco group and required additional intervention for IOP control compared with the Phaco_trab group (39% vs 10%; P = 0.028). This trend continued at 24 months, but no significant differences in failure rates were seen between the groups (P = 0.522).

To access this study, go to the journal's website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.